UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?

Movement disorders, 2013-01, Vol.28 (1), p.31-40

2013

Volltextzugriff (PDF)

Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities

Movement disorders, 2020-10, Vol.35 (10), p.1731-1744

2020

Volltextzugriff (PDF)

Levodopa: A new look at an old friend

Movement disorders, 2018-07, Vol.33 (6), p.859-866

2018

Volltextzugriff (PDF)

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease

Brain (London, England : 1878), 2013-08, Vol.136 (Pt 8), p.2419-2431

2013

Volltextzugriff (PDF)

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity

Movement disorders, 2022-01, Vol.37 (1), p.6-15

2022

Volltextzugriff (PDF)

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

The Lancet (British edition), 2014-08, Vol.384 (9942), p.545-555

2014

Volltextzugriff (PDF)

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

Movement disorders, 2013-07, Vol.28 (8), p.1064-1071

2013

Volltextzugriff (PDF)

Huntington's disease: Current and future therapeutic prospects

Movement disorders, 2018-07, Vol.33 (7), p.1033-1041

2018

Volltextzugriff (PDF)

On‐Demand Therapy for OFF Episodes in Parkinson's Disease

Movement disorders, 2021-10, Vol.36 (10), p.2244-2253

2021

Volltextzugriff (PDF)

Levodopa: Effect on cell death and the natural history of Parkinson's disease

Movement disorders, 2015-01, Vol.30 (1), p.37-44

Olanow, C. Warren

2015

Volltextzugriff (PDF)

Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease

Brain (London, England : 1878), 2019-06, Vol.142 (6), p.1690-1700

2019

Volltextzugriff (PDF)

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Neurology, 2009-05, Vol.72 (21 Suppl 4), p.S1

2009

Volltextzugriff (PDF)

MDS research criteria for prodromal Parkinson's disease

Movement disorders, 2015-10, Vol.30 (12), p.1600-1611

2015

Volltextzugriff (PDF)

A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic

Movement disorders, 2021-01, Vol.36 (1), p.59-63

2021

Volltextzugriff (PDF)

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

Annals of neurology, 2015-08, Vol.78 (2), p.248-257

2015

Volltextzugriff (PDF)

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

Lancet neurology, 2020-02, Vol.19 (2), p.135-144

2020

Volltextzugriff (PDF)

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

Neurology, 2013-04, Vol.80 (18), p.1698-1701

2013

Volltextzugriff (PDF)

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

Nature medicine, 2008-05, Vol.14 (5), p.504-506

2008

Volltextzugriff (PDF)

Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease

Brain (London, England : 1878), 2020-03, Vol.143 (3), p.960-975

2020

Volltextzugriff (PDF)

Is Parkinson's disease a prion disorder?

Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (31), p.12571-12572

2009

Volltextzugriff (PDF)

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

Lancet neurology, 2015-08, Vol.14 (8), p.855-866

2015

Volltextzugriff (PDF)

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease

Movement disorders, 2014-04, Vol.29 (4), p.454-462

2014

Volltextzugriff (PDF)

Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions

Neurobiology of disease, 2009-09, Vol.35 (3), p.385-398

2009

Volltextzugriff (PDF)

Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr

Movement disorders, 2015-01, Vol.30 (1), p.19-36

2015

Volltextzugriff (PDF)

The Neuropathology of Manganese-Induced Parkinsonism

Journal of neuropathology and experimental neurology, 2007-08, Vol.66 (8), p.675-682

2007

Volltextzugriff (PDF)

1 – 25 von 433

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(373)
Mit Volltextzugriff
(344)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(310)
Life Sciences & Biomedicine
(306)
Neurosciences & Neurology
(274)
Clinical Neurology
(243)
Humans
(233)
Parkinson's Disease
(140)
Biological And Medical Sciences
(111)
Medical Sciences
(109)
Neurology
(104)
Parkinson Disease - Drug Therapy
(86)
Neurosciences
(82)
Female
(80)
Male
(79)
Middle Aged
(68)
Animals
(66)
Aged
(60)
Movement Disorders
(53)
Parkinson Disease - Physiopathology
(45)
Antiparkinson Agents - Therapeutic Use
(40)
Adult
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Movement Disorders
(111)
Annals Of Neurology
(81)
Neurology
(41)
Lancet Neurology
(18)
The New England Journal Of Medicine
(10)
Archives Of Neurology
(9)
Cell Transplantation
(8)
Clinical Neuropharmacology
(8)
Experimental Neurology
(6)
Journal Of Neurochemistry
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?

Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities

Levodopa: A new look at an old friend

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

Huntington's disease: Current and future therapeutic prospects

On‐Demand Therapy for OFF Episodes in Parkinson's Disease

Levodopa: Effect on cell death and the natural history of Parkinson's disease

Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease

The scientific and clinical basis for the treatment of Parkinson disease (2009)

MDS research criteria for prodromal Parkinson's disease

A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease

Is Parkinson's disease a prion disorder?

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease

Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions

Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr

The Neuropathology of Manganese-Induced Parkinsonism

Suchergebnisse filtern